Thursday, October 23, 2008

KOLs - the best that money can buy

GlaxoSmithKline is to make public the level of advisory fees it offers to doctors and medical academics, and will strictly cap the payments they can receive in the US to $150,000 (£88,000) a year each.

Andrew Witty, chief executive of the UK-based pharmaceutical company, said he was introducing tougher new rules to impose a cap "without exception" on such payments and promised to publish the amounts.

His commitment comes at a time of growing concern that the widespread practice of payments by pharmaceutical companies may help unfairly influence "key opinion leaders" (KOLs) in the medical community, in a way that biases their judgments and recommendations for particular treatments.

More at FT

1 comment:

Anonymous said...

CEO Andrew Witty told the FT, “In the past, whatever has happened has happened...."

Priceless $$$$ quote